Evidence map›Paper›PMID 39958358›Full record

ArticleFrontiers in immunology2025

PD-L1 knockout or ZG16 overexpression inhibits PDAC progression and modulates TAM polarization.

Hui Meng, Manman Nan, Yizhen Li, Yi Ding, Xiaokun Fang, Weiqian Ma, Mingzhi Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hui Meng *Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Manman Nan *Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yizhen LiDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yi DingDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xiaokun FangDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Weiqian MaDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Mingzhi ZhangDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR/Cas9-mediated genome editing has the potential to delete PD-L1 both on the cell surface and inside the cell, thereby inhibiting tumor growth and migration and overcoming immunosuppression. ZG16, with its lectin structure, can reduce PD-L1 expression on the cell surface. However, direct comparison of two approaches on PD-L1 expression in Pancreatic ductal adenocarcinoma (PDAC) cells has not yet been investigated. In this study, we established two Panc-1 cell line: one with PD-L1 knockout and another with ZG16 overexpression. Both methods promoted the polarization of tumor-associated macrophages (TAMs) to the M1 phenotype, as indicated by increased levels of the M1 marker CD11c+

Indexed as

B7-H1 AntigenCarcinoma, Pancreatic DuctalPancreatic NeoplasmsTumor-Associated MacrophagesAnimalsCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticGene Knockout TechniquesHumansMiceTumor MicroenvironmentB7-H1 AntigenCD274 protein, humanCRISPR/Cas9PDAC progressionPD-L1 knockoutTAM polarizationZG16 intervention

Identifiers

PMID39958358
PMCPMC11826313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.